Resistant Hypertension in Chronic Kidney Disease

(Brent) #1

136



  1. Kanbay M, Turgut F, Uyar ME, Akcay A, Covic A.  Causes and mechanisms of nondipping
    hypertension. Clin Exp Hypertens. 2008;30(7):585–97.

  2. Borrelli S, De Nicola L, Stanzione G, Conte G, Minutolo R. Resistant hypertension in nondi-
    alysis chronic kidney disease. Int J Hypertens. 2013;2013:929183.

  3. Bangash F, Agarwal R. Masked hypertension and white-coat hypertension in chronic kidney
    disease: a meta-analysis. Clin J Am Soc Nephrol. 2009;4(3):656–64.

  4. Ridao N, Luño J, García de Vinuesa S, Gómez F, Tejedor A, Valderrábano F.  Prevalence of
    hypertension in renal disease. Nephrol Dial Transplant. 2001;16(Suppl 1):70–3.

  5. Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, et al. Hypertension aware-
    ness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency
    Cohort (CRIC) study. Am J Kidney Dis. 2010;55(3):441–51.

  6. Curtis JJ, Luke RG, Dustan HP, Kashgarian M, Whelchel JD, Jones P, et  al. Remission of
    essential hypertension after renal transplantation. N Engl J Med. 1983;309(17):1009–15.

  7. Herrera M, Coffman TM. The kidney and hypertension: novel insights from transgenic mod-
    els. Curr Opin Nephrol Hypertens. 2012;21(2):171–8.

  8. Keller G, Zimmer G, Mall G, Ritz E, Amann K.  Nephron number in patients with primary
    hypertension. N Engl J Med. 2003;348(2):101–8.

  9. Widgren BR, Herlitz H, Hedner T, Berglund G, Wikstrand J, Jonsson O, et al. Blunted renal
    sodium excretion during acute saline loading in normotensive men with positive family histo-
    ries of hypertension. Am J Hypertens. 1991;4(7 Pt 1):570–8.

  10. Todd AS, Macginley RJ, Schollum JB, Johnson RJ, Williams SM, Sutherland WH, et  al.
    Dietary salt loading impairs arterial vascular reactivity. Am J Clin Nutr. 2010;91(3):557–64.

  11. Al-Solaiman Y, Jesri A, Zhao Y, Morrow JD, Egan BM.  Low-Sodium DASH reduces oxi-
    dative stress and improves vascular function in salt-sensitive humans. J  Hum Hypertens.
    2009;23(12):826–35.

  12. McMahon EJ, Bauer JD, Hawley CM, Isbel NM, Stowasser M, Johnson DW, et al. A random-
    ized trial of dietary sodium restriction in CKD. J Am Soc Nephrol. 2013;24(12):2096–103.

  13. Vasavada N, Agarwal R.  Role of excess volume in the pathophysiology of hypertension in
    chronic kidney disease. Kidney Int. 2003;64(5):1772–9.

  14. Saad E, Charra B, Raj DS.  Hypertension control with daily dialysis. Semin Dial.
    2004;17(4):295–8.

  15. Ok E, Duman S, Asci G, Tumuklu M, Onen Sertoz O, Kayikcioglu M, et al. Comparison of
    4- and 8-h dialysis sessions in thrice-weekly in-centre haemodialysis: a prospective, case-
    controlled study. Nephrol Dial Transplant. 2011;26(4):1287–96.

  16. Günal AI, Duman S, Ozkahya M, Töz H, Asçi G, Akçiçek F, et al. Strict volume control nor-
    malizes hypertension in peritoneal dialysis patients. Am J Kidney Dis. 2001;37(3):588–93.

  17. Kobori H, Nangaku M, Navar LG, Nishiyama A.  The intrarenal renin-angiotensin system:
    from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev.
    2007;59(3):251–87.

  18. Weidmann P, Maxwell MH, Lupu AN, Lewin AJ, Massry SG. Plasma renin activity and blood
    pressure in terminal renal failure. N Engl J Med. 1971;285(14):757–62.

  19. Vaughan ED, Carey RM, Ayers CR, Peach MJ. Hemodialysis-resistant hypertension: control
    with an orally active inhibitor of angiotensin-converting enzyme. J  Clin Endocrinol Metab.
    1979;48(5):869–71.

  20. Briet M, Schiffrin EL. Vascular actions of aldosterone. J Vasc Res. 2013;50(2):89–99.

  21. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat.
    J Clin Invest. 1996;98(4):1063–8.

  22. Ibrahim HN, Hostetter TH. The renin-aldosterone axis in two models of reduced renal mass in
    the rat. J Am Soc Nephrol. 1998;9(1):72–6.

  23. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M, et al. Renal sympa-
    thetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2
    Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9.


F. Turgut et al.
Free download pdf